Form 4/A for ELVN Enliven Therapeutics, Inc.
Accepted 2023-01-05 00:00:00 ET · period of report 2023-01-03 · accession 0001567619-23-000570 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AI | 2023-01-05 | 2023-01-03 | ELVN | Leonard Braden Michael | 10% | S - Sale | $4.00 | -1.25M | 1.77M | -41% | -$5.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-03 | S | D | 1,250,000 | $4.00 | 1,767,774 | I Holding of BML Investment Partners, L.P. | — | — | (F2) This form was filed to correct the transaction date to 1/3/2023. (F1) BML Capital Management, LLC ("BML Capital") serves as the general partner of BML Investment Partners, L.P., a Delaware limited partnership (the "Fund"), which is the direct owner of the subject shares. Mr. Leonard is the managing member of BML Capital, and exercises investment and voting control over the subject shares. Accordingly, shares owned directly by the Fund may be regarded as being beneficially owned by Mr. Leonard. Notwithstanding, Mr. Leonard disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |